Imagion Biosystems

Imagion Biosystems EBITDA per Share

The EBITDA per Share of Imagion Biosystems (IBX.AX) as of Oct 31, 2026 is -0.01 AUD. In the previous year, EBITDA per Share was -0.01 AUD — a change of 52.32% (lower).

EBITDA per Share

-0.01AUD

YoY

52.32%

Last updated:

EBITDA per Share of Imagion Biosystems is 2025 -0.01 AUD. EBITDA per Share of Imagion Biosystems was 2024 -0.01 AUD. It decreases by 52.32% lower compared to the previous year.

The Imagion Biosystems EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-1.37 AUD
Jan 1, 2019
-0.01 AUD
Jan 1, 2020
-0.01 AUD
Jan 1, 2021
-0.01 AUD
Jan 1, 2022
-0.39 AUD
Jan 1, 2023
-0.42 AUD
Jan 1, 2024
-0.01 AUD
Jan 1, 2025
-0.01 AUD
The Imagion Biosystems EBITDA per Share history
YEAREBITDA per ShareYoY
-0.01AUD+52.32%
-0.01AUD-98.49%
-0.42AUD+7.21%
-0.39AUD+5,473.97%
-0.01AUD-4.78%
-0.01AUD+22.47%
-0.01AUD-99.56%
-1.37AUD+4,725.85%
-0.03AUD+856.45%
-0.00AUD-100.00%
-201.22AUD+77.84%
-113.14AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imagion Biosystems Stock analysis

What does Imagion Biosystems do? Imagion Biosystems Ltd develops non-radioactive diagnostic imaging technology through its MagSense and PrecisionMRX product lines. MagSense uses cancer-specific magnetic nanoparticles for detecting breast, prostate, and ovarian cancers, with a Phase I clinical study ongoing for its HER2 imaging agent. PrecisionMRX offers coated nanoparticles including Dextran-Coated, mPEG Coated, Oleic Acid Coated, and Carboxylic Acid Functionalized variants for magnetic relaxometry applications. The company generates revenue primarily through research and development activities, focusing on advanced cancer diagnostics and medical imaging solutions. The firm operates exclusively in the Research and Development segment, targeting medical professionals and healthcare institutions requiring innovative diagnostic tools. MagSense technology is designed as an injectable solution tailored to specific cancer types, while PrecisionMRX nanoparticles serve biomedical applications demanding high precision. These products are developed for use in cancer diagnostics, with clinical studies validating their effectiveness in detecting critical diseases. Imagion Biosystems' revenue streams derive from the development and commercialization of its proprietary imaging technologies. The company's MagSense platform enables functional imaging for cancer detection without radioactive materials, appealing to healthcare providers seeking safer diagnostic alternatives. PrecisionMRX nanoparticles support specialized biomedical applications, offering customizable solutions for medical imaging needs across various cancer types. Imagion Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imagion Biosystems stock

EBITDA per Share of Imagion Biosystems is -0.01 AUD in 2025.

EBITDA per Share of Imagion Biosystems changed from -0.01 AUD to -0.01 AUD, representing a 52.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Imagion Biosystems since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Imagion Biosystems

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Imagion Biosystems